Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $13.9 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas.
Shares of this leading research and diagnostic firm have outperformed the broader market over the past year. RVTY has gained 39.1% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.5%. In 2026, RVTY’s stock rose 28.9%, surpassing the SPX’s 12.1% rise on a YTD basis.
Zooming in further, RVTY’s outperformance is also apparent compared to the State Street Health Care Select Sector SPDR ETF (XLV). The exchange-traded fund has gained about 27.4% on a YTD basis. Moreover, the stock’s returns on a YTD basis outshine the ETF’s 12.8% gains over the same time frame.
RVTY outperformed on Diagnostics strength and accelerating AI-driven demand in Life Sciences. Diagnostics was led by reproductive health and ex-China immunodiagnostics, with newborn screening resilient despite lower birth rates. Management noted improving pharma and biotech spending and strong orders from AI customers building large datasets. The Opera Phenix OptIQ screener saw strong growth, with orders outpacing capacity and lifting backlog, which should drive future reagent demand. The company exited its China immunodiagnostics business and is reinvesting tariff refunds into capacity and innovation, with guidance raised on better end-markets and AI adoption.
For the current fiscal year, ending in December, analysts expect RVTY’s EPS to grow 5.9% to $5.36 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.
Among the 17 analysts covering RVTY stock, the consensus is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, and 11 “Holds.”
This configuration is less bearish than a month ago, with one analyst suggesting a “Strong Sell.”
On Aug. 6, JPMorgan Chase & Co. (JPM) analyst Casey Woodring maintained a “Hold” rating on RVTY and set a price target of $110.
While RVTY currently trades above its mean price target of $119.07, the Street-high price target of $145 suggests an upside potential of 16.2%.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/People%20shopping%20at%20a%20Walmart%20store%20by%20Photography%20via%20Shutterstock.jpg)
